Clinical gene therapy for arthritis

Steven C. Ghivizzani, Thomas S. Muzzonigro, Richard Kang, Christopher H Evans, Paul D. Robbins

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

To overcome problems associated with conventional drug delivery in the treatment of rheumatoid arthritis (RA) our laboratory has been exploring the application of gene transfer as a means to express therapeutic proteins intraarticularly. Initial experiments in rabbit knee joints demonstrated that the gene encoding interleukin (IL)-1 receptor antagonist (IL-1RA) could be delivered to the synovial lining and expressed at a therapeutic level. The success of these experiments has led to the initiation of a clinical trial to assess the safety and efficacy of using gene therapy to treat RA. For this procedure autologous synoviocytes are retrovirally transduced in culture to express IL-1RA, and are transplanted into two metacarpophalangeal (MCP) joints of the hand. For comparative controls non-modified synoviocytes are injected into the remaining two MCP joints. During scheduled joint replacement surgery articular tissues and fluids are recovered and analyzed for expression of the IL-1RA transgene. Nine patients will be treated in groups of three; with each group receiving successively higher numbers of transduced synoviocytes. To date five patients have completed the procedure. Thus far it has been well tolerated and intraarticular expression of the IL- 1 transgene has been detected by both reverse transcriptase-polymerase chain reaction and in situ hybridization analyses. If this procedure indeed proves to be safe and feasible, future trials will address therapeutic efficacy and involve treatment in patients earlier in the progression of RA.

Original languageEnglish (US)
Pages (from-to)389-396
Number of pages8
JournalDrugs of Today
Volume35
Issue number4-5
StatePublished - Apr 1999
Externally publishedYes

Fingerprint

Genetic Therapy
Arthritis
Metacarpophalangeal Joint
Rheumatoid Arthritis
Interleukins
Transgenes
Replacement Arthroplasties
Interleukin-1 Receptors
Therapeutics
Knee Joint
Reverse Transcriptase Polymerase Chain Reaction
Interleukin-1
Genes
In Situ Hybridization
Hand
Joints
Clinical Trials
Rabbits
Safety
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology (medical)
  • Pharmacology

Cite this

Ghivizzani, S. C., Muzzonigro, T. S., Kang, R., Evans, C. H., & Robbins, P. D. (1999). Clinical gene therapy for arthritis. Drugs of Today, 35(4-5), 389-396.

Clinical gene therapy for arthritis. / Ghivizzani, Steven C.; Muzzonigro, Thomas S.; Kang, Richard; Evans, Christopher H; Robbins, Paul D.

In: Drugs of Today, Vol. 35, No. 4-5, 04.1999, p. 389-396.

Research output: Contribution to journalArticle

Ghivizzani, SC, Muzzonigro, TS, Kang, R, Evans, CH & Robbins, PD 1999, 'Clinical gene therapy for arthritis', Drugs of Today, vol. 35, no. 4-5, pp. 389-396.
Ghivizzani SC, Muzzonigro TS, Kang R, Evans CH, Robbins PD. Clinical gene therapy for arthritis. Drugs of Today. 1999 Apr;35(4-5):389-396.
Ghivizzani, Steven C. ; Muzzonigro, Thomas S. ; Kang, Richard ; Evans, Christopher H ; Robbins, Paul D. / Clinical gene therapy for arthritis. In: Drugs of Today. 1999 ; Vol. 35, No. 4-5. pp. 389-396.
@article{f12a8fdc037446879e424422c4d4a6a3,
title = "Clinical gene therapy for arthritis",
abstract = "To overcome problems associated with conventional drug delivery in the treatment of rheumatoid arthritis (RA) our laboratory has been exploring the application of gene transfer as a means to express therapeutic proteins intraarticularly. Initial experiments in rabbit knee joints demonstrated that the gene encoding interleukin (IL)-1 receptor antagonist (IL-1RA) could be delivered to the synovial lining and expressed at a therapeutic level. The success of these experiments has led to the initiation of a clinical trial to assess the safety and efficacy of using gene therapy to treat RA. For this procedure autologous synoviocytes are retrovirally transduced in culture to express IL-1RA, and are transplanted into two metacarpophalangeal (MCP) joints of the hand. For comparative controls non-modified synoviocytes are injected into the remaining two MCP joints. During scheduled joint replacement surgery articular tissues and fluids are recovered and analyzed for expression of the IL-1RA transgene. Nine patients will be treated in groups of three; with each group receiving successively higher numbers of transduced synoviocytes. To date five patients have completed the procedure. Thus far it has been well tolerated and intraarticular expression of the IL- 1 transgene has been detected by both reverse transcriptase-polymerase chain reaction and in situ hybridization analyses. If this procedure indeed proves to be safe and feasible, future trials will address therapeutic efficacy and involve treatment in patients earlier in the progression of RA.",
author = "Ghivizzani, {Steven C.} and Muzzonigro, {Thomas S.} and Richard Kang and Evans, {Christopher H} and Robbins, {Paul D.}",
year = "1999",
month = "4",
language = "English (US)",
volume = "35",
pages = "389--396",
journal = "Drugs of Today",
issn = "1699-3993",
publisher = "Prous Science",
number = "4-5",

}

TY - JOUR

T1 - Clinical gene therapy for arthritis

AU - Ghivizzani, Steven C.

AU - Muzzonigro, Thomas S.

AU - Kang, Richard

AU - Evans, Christopher H

AU - Robbins, Paul D.

PY - 1999/4

Y1 - 1999/4

N2 - To overcome problems associated with conventional drug delivery in the treatment of rheumatoid arthritis (RA) our laboratory has been exploring the application of gene transfer as a means to express therapeutic proteins intraarticularly. Initial experiments in rabbit knee joints demonstrated that the gene encoding interleukin (IL)-1 receptor antagonist (IL-1RA) could be delivered to the synovial lining and expressed at a therapeutic level. The success of these experiments has led to the initiation of a clinical trial to assess the safety and efficacy of using gene therapy to treat RA. For this procedure autologous synoviocytes are retrovirally transduced in culture to express IL-1RA, and are transplanted into two metacarpophalangeal (MCP) joints of the hand. For comparative controls non-modified synoviocytes are injected into the remaining two MCP joints. During scheduled joint replacement surgery articular tissues and fluids are recovered and analyzed for expression of the IL-1RA transgene. Nine patients will be treated in groups of three; with each group receiving successively higher numbers of transduced synoviocytes. To date five patients have completed the procedure. Thus far it has been well tolerated and intraarticular expression of the IL- 1 transgene has been detected by both reverse transcriptase-polymerase chain reaction and in situ hybridization analyses. If this procedure indeed proves to be safe and feasible, future trials will address therapeutic efficacy and involve treatment in patients earlier in the progression of RA.

AB - To overcome problems associated with conventional drug delivery in the treatment of rheumatoid arthritis (RA) our laboratory has been exploring the application of gene transfer as a means to express therapeutic proteins intraarticularly. Initial experiments in rabbit knee joints demonstrated that the gene encoding interleukin (IL)-1 receptor antagonist (IL-1RA) could be delivered to the synovial lining and expressed at a therapeutic level. The success of these experiments has led to the initiation of a clinical trial to assess the safety and efficacy of using gene therapy to treat RA. For this procedure autologous synoviocytes are retrovirally transduced in culture to express IL-1RA, and are transplanted into two metacarpophalangeal (MCP) joints of the hand. For comparative controls non-modified synoviocytes are injected into the remaining two MCP joints. During scheduled joint replacement surgery articular tissues and fluids are recovered and analyzed for expression of the IL-1RA transgene. Nine patients will be treated in groups of three; with each group receiving successively higher numbers of transduced synoviocytes. To date five patients have completed the procedure. Thus far it has been well tolerated and intraarticular expression of the IL- 1 transgene has been detected by both reverse transcriptase-polymerase chain reaction and in situ hybridization analyses. If this procedure indeed proves to be safe and feasible, future trials will address therapeutic efficacy and involve treatment in patients earlier in the progression of RA.

UR - http://www.scopus.com/inward/record.url?scp=0032777810&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032777810&partnerID=8YFLogxK

M3 - Article

C2 - 12973441

AN - SCOPUS:0032777810

VL - 35

SP - 389

EP - 396

JO - Drugs of Today

JF - Drugs of Today

SN - 1699-3993

IS - 4-5

ER -